GS
XLO icon

Gilead Sciences’s Xilio Therapeutics XLO Stock Holding History

Gilead Sciences’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.23M Hold
650,389
– – 0.38% 5
2026
Q1 		$5.47M Hold
650,389
– – 0.26% 6
2025
Q4 		$5.83M Hold
650,389
– – 0.3% 6
2025
Q3 		$7.67M Hold
650,389
– – 0.43% 8
2025
Q2 		$6.19M Hold
650,389
– – 0.48% 8
2025
Q1 		$6.6M Hold
650,389
– – 0.56% 8
2024
Q4 		$8.7M Buy
+650,389
New +$8.95M 0.56% 9

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Gilead Sciences's XLO Position: Q2 2026 in Review

Gilead Sciences held its Xilio Therapeutics (XLO) position steady in Q2 2026 at 650,389 shares worth $6.23M. The position accounts for 0.38% of the portfolio, ranked #5.

Gilead Sciences first reported a position in XLO in Q4 2024 and has held it in 7 quarters since. The position peaked at $8.7M in Q4 2024. 26 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • Gilead Sciences held 650,389 shares of Xilio Therapeutics worth $6.23M as of Q2 2026.
  • Gilead Sciences left its Xilio Therapeutics share count unchanged in Q2 2026.
  • Xilio Therapeutics made up 0.38% of Gilead Sciences's portfolio in Q2 2026, its #5 holding.
  • Gilead Sciences first reported a position in Xilio Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Gilead Sciences's Xilio Therapeutics position peaked at $8.7M in Q4 2024.
  • 26 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Gilead Sciences's 13F filing for Q2 2026, filed 3 Aug 2026.